Rilotumumab

Description

Rilotumumab is an anti-HGF antibody that prevents ligand binding to MET and its activation.

Uses

Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research[1][2].

Clinical Use

A phase I/II trial of rilotumumab in combination with erlotinib was evaluated in previously treated NSCLC patients with metastatic disease. The results indicated a favorable safety profile and success in terms of disease control rate. A phase Ib/II trial of rilotumumab or ganitumab in combination with etoposide and carboplatin or cisplatin was evaluated in extensive-stage SCLC patients.

in vivo

References

[1] Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24. DOI:10.1158/1078-0432.CCR-12-2605
[2] Greenall SA, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015 Oct 8;34(41):5277-87. DOI:10.1038/onc.2014.448